uniQure N.V. $QURE Shares Sold by Jennison Associates LLC

Jennison Associates LLC cut its holdings in uniQure N.V. (NASDAQ:QURE) by 10.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,233,789 shares of the biotechnology company’s stock after selling 137,401 shares during the period. Jennison Associates LLC’s holdings in uniQure were worth $20,172,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Torren Management LLC acquired a new stake in uniQure during the fourth quarter worth $28,000. IFP Advisors Inc purchased a new stake in uniQure in the fourth quarter valued at $48,000. Smartleaf Asset Management LLC purchased a new stake in uniQure in the fourth quarter valued at $48,000. CIBC Private Wealth Group LLC acquired a new position in shares of uniQure in the 3rd quarter valued at $50,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of uniQure by 42.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 906 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Price Performance

Shares of QURE opened at $40.09 on Wednesday. The firm has a market capitalization of $2.53 billion, a price-to-earnings ratio of -11.52 and a beta of 0.90. The firm’s fifty day simple moving average is $35.24 and its 200-day simple moving average is $25.34. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Equities analysts forecast that uniQure N.V. will post -3.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jack Kaye sold 21,167 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total transaction of $982,995.48. Following the sale, the director owned 25,996 shares of the company’s stock, valued at approximately $1,207,254.24. This trade represents a 44.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total value of $1,392,600.00. Following the sale, the insider directly owned 148,235 shares in the company, valued at $6,881,068.70. This trade represents a 16.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 433,229 shares of company stock valued at $17,944,799 over the last quarter. Corporate insiders own 4.65% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on QURE shares. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective for the company in a research report on Wednesday, June 17th. Royal Bank Of Canada boosted their price objective on shares of uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Leerink Partners increased their target price on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Finally, Barclays upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $25.00 to $65.00 in a research report on Thursday, June 18th. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $64.17.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.